Suggestions
James Hardiman
General Partner at DCVC - focused on early stage, applied AI & deep tech investments
James Hardiman is a prominent investor and board director currently associated with NOETIK, an AI-native biotechnology company focused on developing cancer therapeutics. He serves as a General Partner at Data Collective DCVC, where he has been investing since 2013. His investment interests span several advanced technologies, including biotechnology, robotics, artificial intelligence, and quantum computing.12
Hardiman holds a Bachelor's degree in Engineering Physics from the University of California, Berkeley, and an MBA from the University of Chicago Booth School of Business. His professional background includes significant experience in data-driven strategies within the life sciences and healthcare sectors, as well as roles in research and development of new materials and semiconductor processing.123
At NOETIK, Hardiman plays a crucial role in guiding the company's strategic direction and investment initiatives. Recently, he was involved in securing a $40 million Series A financing round for NOETIK, aimed at enhancing its capabilities in precision oncology and cancer therapy development.34
Highlights
Excited to announce @DCVC's investment in Alta!
Rare earths are critical in products from magnets to ceramics & we need our own supply chain
Through computationally optimized proteins Alta brings rare earth production back - cleaner and cheaper
